NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. reached the public markets through its combination with Big Rock Partners Acquisition Corp. (Nasdaq: BRPA), a blank-check vehicle sponsored by Big Rock Partners LLC that completed its initial public offering in 2018. The SPAC targeted the healthcare and life sciences sector, ultimately closing its de-SPAC transaction with NRX Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders and critical care conditions. On December 29, 2023, NRX Pharmaceuticals filed an 8-K with the Securities and Exchange Commission disclosing a material corporate development. For complete filing history, sponsor profiles, and deal-level analytics on BRPA and the broader SPAC universe, sign up for full data access at SpacDesk.